Abstract:Background: A systematic search was performed on the Web of Science, PubMed, Embase, and Cochrane databases. The meta-analysis was performed to evaluate the effect of epidermal growth factor receptor (EGFR) mutation status on programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors, and the association between EGFR mutation status and PD-L1 expression in non-small cell lung cancer (NSCLC) patients.Methods: Pooled effect (HR/OR) with 95% CI was calculated, the source of heterogeneity was explored by subgroup analysis and meta-regression using Stata/SE 15.0. Meta-analysis of the association between EGFR mutation status and overall survival in NSCLC with immunotherapy was calculated from four randomized controlled trials. Results: We found that immune checkpoint inhibitors significantly prolonged overall survival (OS) over docetaxel overall (HR: 0.71, 95% CI: 0.64-0.79) and in the EGFR wild-type (HR=0.67, 95% CI=0.60-0.75), but not in the EGFR-mutant subgroup (HR=1.11, 95% CI=0.80-1.52). Meta-analysis of the association between EGFR mutation status and PD-L1 expression in NSCLC included 32 studies. The pooled OR and 95% CI were 0.60 (0.46 0.80), calculated by random effects model. No source of heterogeneity was found in subgroup analysis. The sensitivity analysis was carried out with a fixed model, and the influence of a single study on the pooled results showed no significant change with robust meta-analysis methods. Harbord s weighted linear regression test (P=0.956) and Peters regression test (P=0.489) indicated no significant publication bias. Conclusions: The benefit of PD-1/PD-L1 immune checkpoint inhibitor treatment in patients with EGFR-mutated NSCLC is not obvious and may due to the lower expression of PD-L1.Funding: This study was supported by Fujian Program for Outstanding Young Researchers in University awarded by Education Department of Fujian (Grant Number 2017B019), Fujian Provincial Health Research Talents Training Programme Medical Innovation Project (Grant Number 2019- CX-33), Joint Funds for the innovation of science and Technology，Fujian province (Grant Number 2019Y9022), and Fujian Provincial Health Research Talents Training Programme Youth Research Project (Grant Number 2019-1- 58).The funding sponsors played no role in study design, data collection, data analysis, interpretation, writing of the report, and the decision to submit the paper for publication.Declaration of Interest: None to declare. Ethical Approval: This study was approved by the Institutional Review Board of Fujian Medical University (Fuzhou, China).

Association of CD8 T cell apoptosis and <i>EGFR</i> mutation in non-small lung cancer patients

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

JCES 01.19 EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in NSCLC

EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in Non-Small Cell Lung Cancer

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Epidermal Growth Factor Receptor Gene Mutations in Non-Small-cell Lung Cancer Cells Are Associated with Increased Radiosensitivity in Vitro

Investigation of immune microenvironment in EGFR mutant NSCLC.

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

443O EGFR Mutations Are Associated with Unfavourable Efficacy to Anti-Pd1 Therapy in NSCLC

Sensitization of Epidermal Growth Factor Receptor (EGFR) Inhibitors Induced by Radiotherapy Combined with Programmed Death Ligand-1 (PD-L1) Inhibitors

Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Association Between EGFR Mutation Status and Immune Checkpoint Inhibitors and PD-L1 Expression in Non-Small-Cell Lung Cancer: A Meta-Analysis

The Association Between PD-L1 and EGFR Status and the Prognostic Value of PD-L1 in Advanced Non-Small Cell Lung Cancer Patients Treated with EGFR-TKIs

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.